Save Product
Product Details
Synonyms
TIGIT, VSIG9, VSTM3
Source
Human TIGIT, Mouse IgG2a Fc Tag (TIT-H5253) is expressed from human 293 cells (HEK293). It contains AA Met 22 - Pro 141 (Accession # Q495A1-1).
Predicted N-terminus: Met 22
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a mouse IgG2a Fc tag at the C-terminus.
The protein has a calculated MW of 40.1 kDa. The protein migrates as 45-50 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 0.01 EU per μg by the LAL method / rFC method.
Purity
>95% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Shipping and Storage
This product is shipped at ambient temperature.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Human TIGIT, Mouse IgG2a Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
SEC-MALS
The purity of Human TIGIT, Mouse IgG2a Fc Tag (Cat. No. TIT-H5253) is more than 95% and the molecular weight of this protein is around 80-105 kDa verified by SEC-MALS.
Report
Bioactivity-ELISA
Immobilized Human CD155, Fc Tag (Cat. No. CD5-H5251) at 5 μg/mL (100 μL/well) can bind Human TIGIT, Mouse IgG2a Fc Tag (Cat. No. TIT-H5253) with a linear range of 0.5-4 ng/mL (QC tested).
Protocol
Serial dilutions of TIGIT Antibody (1:2 serial dilutions, from 20 μg/mL to 0.0097 μg/mL) were added into Human TIGIT, Mouse IgG2a Fc Tag (Cat. No. TIT-H5253): Biotinylated Human Nectin-2, Fc,Avitag (Cat. No. CD2-H82F8) binding reactions. The assay was performed according to the above described protocol. Background was subtracted from data points before curve fitting.
Protocol
Bioactivity-BLI
Loaded Human TIGIT, Mouse IgG2a Fc Tag (Cat. No. TIT-H5253) on Protein A Biosensor, can bind Human CD155, His Tag (Cat. No. CD5-H5223) with an affinity constant of 0.92 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Protocol
Bioactivity-Flow Cytometry
FACS assay shows that Human TIGIT, Mouse IgG2a Fc Tag (Cat. No. TIT-H5253) can bind to 293T cell overexpressing human CD155. The concentration of TIGIT used is 0.03 μg/mL (Routinely tested).
Protocol
Customer Reviews Writing Reviews
1***32019-10-11
LikesI have used Acro products in other projects, and the quality is comparable to RnD Systems products. The purpose of buying this protein was mainly for immunization and screening, and we finally got candidate molecules.
FAQ
- product
Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?
In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.
Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.
To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.
To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.
Supporting Document
Background
Recent Advances
Drug Development Progress- English Name：
T cell immunoglobulin and ITIM domains
- Category：
- Approved Drugs：
0 Details
- Drugs in Clinical Trials：
41 Details
- Highest Development Stage：
Phase 3 Clinical
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
